Zoledronic acid - Sagent Pharmaceuticals
Latest Information Update: 23 Jul 2015
At a glance
- Originator Allergan
- Developer Sagent Pharmaceuticals
- Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; Geranylgeranyltransferase inhibitors; Osteoclast inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Bone metastases; Malignant hypercalcaemia; Multiple myeloma; Prostate cancer